Literature DB >> 31560059

Elevated tau PET signal depends on abnormal amyloid levels and is uncommon in unimpaired individuals.

Brian A Gordon1, Betty M Tijms2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31560059      PMCID： PMC7962905          DOI： 10.1093/brain/awz278

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  10 in total

1.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

Review 2.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.

Authors:  J C Morris; J L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

3.  Alzheimer's disease: where next for anti-amyloid therapies?

Authors:  John Hardy; Bart De Strooper
Journal:  Brain       Date:  2017-04-01       Impact factor: 13.501

4.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Authors:  Rik Ossenkoppele; Daniel R Schonhaut; Michael Schöll; Samuel N Lockhart; Nagehan Ayakta; Suzanne L Baker; James P O'Neil; Mustafa Janabi; Andreas Lazaris; Averill Cantwell; Jacob Vogel; Miguel Santos; Zachary A Miller; Brianne M Bettcher; Keith A Vossel; Joel H Kramer; Maria L Gorno-Tempini; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Brain       Date:  2016-03-08       Impact factor: 13.501

Review 5.  Tau imaging: early progress and future directions.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Colin L Masters; Christopher C Rowe
Journal:  Lancet Neurol       Date:  2015-01       Impact factor: 44.182

6.  The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.

Authors:  Brian A Gordon; Karl Friedrichsen; Matthew Brier; Tyler Blazey; Yi Su; Jon Christensen; Patricia Aldea; Jonathan McConathy; David M Holtzman; Nigel J Cairns; John C Morris; Anne M Fagan; Beau M Ances; Tammie L S Benzinger
Journal:  Brain       Date:  2016-06-10       Impact factor: 13.501

Review 7.  A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.

Authors:  Francesco Panza; Bruno P Imbimbo; Madia Lozupone; Giancarlo Logroscino
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

8.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Authors:  Michael J Pontecorvo; Michael D Devous; Michael Navitsky; Ming Lu; Stephen Salloway; Frederick W Schaerf; Danna Jennings; Anupa K Arora; Anne McGeehan; Nathaniel C Lim; Hui Xiong; Abhinay D Joshi; Andrew Siderowf; Mark A Mintun
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

9.  Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.

Authors:  Anne M Fagan; Mark A Mintun; Aarti R Shah; Patricia Aldea; Catherine M Roe; Robert H Mach; Daniel Marcus; John C Morris; David M Holtzman
Journal:  EMBO Mol Med       Date:  2009-11       Impact factor: 12.137

10.  The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.

Authors:  Clifford R Jack; Heather J Wiste; Hugo Botha; Stephen D Weigand; Terry M Therneau; David S Knopman; Jonathan Graff-Radford; David T Jones; Tanis J Ferman; Bradley F Boeve; Kejal Kantarci; Val J Lowe; Prashanthi Vemuri; Michelle M Mielke; Julie A Fields; Mary M Machulda; Christopher G Schwarz; Matthew L Senjem; Jeffrey L Gunter; Ronald C Petersen
Journal:  Brain       Date:  2019-10-01       Impact factor: 13.501
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.